Best P J, Daoud M S, Pittelkow M R, Petitt R M
Mayo Clinic, Rochester, Minnesota, USA.
Ann Intern Med. 1998 Jan 1;128(1):29-32. doi: 10.7326/0003-4819-128-1-199801010-00005.
Hydroxyurea is an antineoplastic agent commonly used to treat myeloproliferative disorders and other nonneoplastic conditions.
To further define the typical features of hydroxyurea-related cutaneous ulcers of the leg.
Retrospective, descriptive study of the medical records of patients who developed leg ulcers while receiving hydroxyurea therapy.
A tertiary care medical center.
Patients with myeloproliferative disorders who were treated with hydroxyurea.
14 patients with extremely painful leg ulcers were identified. The most common ulcer site was the malleoli. Multiple ulcers were seen in 64% of patients. Patients had received hydroxyurea for an average of 6 years before ulcers developed. All ulcers healed after discontinuation of hydroxyurea treatment, and 2 patients developed ulcers after treatment was restarted.
Hydroxyurea induces painful leg ulcers that are usually difficult to treat and require cessation of hydroxyurea therapy.
羟基脲是一种常用于治疗骨髓增殖性疾病和其他非肿瘤性疾病的抗肿瘤药物。
进一步明确羟基脲相关的腿部皮肤溃疡的典型特征。
对接受羟基脲治疗期间发生腿部溃疡的患者病历进行回顾性描述性研究。
一家三级医疗中心。
接受羟基脲治疗的骨髓增殖性疾病患者。
确定了14例腿部溃疡剧痛的患者。最常见的溃疡部位是内、外踝。64%的患者有多处溃疡。患者在溃疡发生前平均接受羟基脲治疗6年。停用羟基脲治疗后所有溃疡均愈合，2例患者在重新开始治疗后出现溃疡。
羟基脲可诱发疼痛性腿部溃疡，通常难以治疗，需要停用羟基脲治疗。
